Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Mircera for anaemia
Mircera is the only FDA-approved erythropoiesis-stimulating agent (ESA) to provide correction of anemia with once-every-two-week dosing. Mircera is also the only FDA-approved ESA to maintain stable hemoglobin levels
Mircera is the only FDA-approved erythropoiesis-stimulating agent (ESA) to provide correction of anemia with once-every-two-week dosing. Mircera is also the only FDA-approved ESA to maintain stable hemoglobin levels
The products will be based on a combination of intellectual property (IP) from Hadasit and Anadis. Hadasit will contribute user specific methods for the treatment of immune mediated
The cash purchase price includes the purchase of certain real estate assets utilized by the business which will be sold simultaneously with the closing of the transaction to
Researchers at the University of Leuven and ThromboGenics have developed a novel therapeutic approach, showing that the inhibition of VPAC could stimulate the production of platelets. ThromboGenics has
The underwriters have options to purchase approximately 279,000 additional shares of preferred stock and approximately 8.025 million shares of common stock, in each case to cover over-allotments, if
Under the terms of the settlement, Schering-Plough will receive a license to OraSure’s patents in the US over-the-counter (OTC) market and OraSure will receive payments of past and
The goal of the joint venture, which the companies will be finalizing over the next several months, is to utilize the Andara oscillating field stimulator (OFS) technology to
The independent study (NCIC CTG CO.17) involved 572 patients and demonstrated that treating patients with Erbitux as a monotherapy plus best supportive care (BSC) significantly increased overall survival
In this head-to-head comparator study, the increase in lumbar spine bone mineral density (BMD) was significantly greater in patients receiving teriparatide compared with alendronate at 6, 12, and
Individuals in the study were assessed two years after NX-1207 treatment for symptomatic improvement, treatment outcomes, and durability of efficacy. This is the largest cohort of patients treated